PROMIS NEUROSCIENCES INC. Income (Loss) from Equity Method Investments
PROMIS NEUROSCIENCES INC. (PMN) reported Income (Loss) from Equity Method Investments of -$2.37 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Other Income
us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2022-11-14
- 2021-09-30: Income (Loss) from Equity Method Investments 9 month -$2.37K.
| Period end | Income (Loss) from Equity Method Investments 9 month |
|---|---|
| 2021-09-30 | -$2.37K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |